Geographic differences in heart failure trials.

Area of Science:

• Cardiology
• Clinical Trials
• Health Services Research

Background:

• Randomized controlled trials (RCTs) are crucial for advancing heart failure (HF) treatment.
• International collaboration in RCTs has increased to manage patient numbers and costs.
• Significant regional variations in patient profiles, outcomes, and treatment efficacy within HF trials have been noted.

Purpose of the Study:

• To investigate the causes of geographic discrepancies in HF clinical trials.
• To analyze data from trials across different regions and HF subtypes (HF-PEF, HF-REF, AHF).
• To propose strategies for mitigating regional differences in future HF research.

Main Methods:

• Review and analysis of existing data from international heart failure RCTs.
• Examination of patient characteristics, outcomes, and treatment effects across diverse geographic regions.
• Focus on trials for heart failure with preserved ejection fraction (HF-PEF), reduced ejection fraction (HF-REF), and acute heart failure (AHF).

Main Results:

• Highlighting significant geographic differences in patient populations and treatment responses within HF trials.
• Identifying potential contributing factors such as trial design, patient heterogeneity, and country-specific healthcare structures.
• Underscoring the particular vulnerability of HF-PEF trials to selection bias due to patient heterogeneity.

Conclusions:

• Regional variations in HF trials pose challenges to generalizing research findings.
• Addressing these discrepancies is essential for developing effective and broadly applicable HF treatments.
• Actionable measures are needed to enhance the reliability and generalizability of future international HF clinical trials, especially for HF-PEF.